Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$29.14 +6.7%	$29.14	$23.42 ▼ $62.58	$1.69B	0.77	696,126 shs	476,389 shs
CNTA Centessa Pharmaceuticals	$13.15 +6.9%	$13.79	$7.75 ▼ $19.09	$1.75B	1.53	625,804 shs	430,445 shs
INDV Indivior	$11.34 +2.3%	$9.99	$7.33 ▼ $18.59	$1.56B	0.98	997,881 shs	579,660 shs
KIN Kindred Biosciences	$9.25	$9.22	$3.46 ▼ $9.28	$420.52M	1.3	840,890 shs	178,496 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	-9.24%	+2.32%	-19.58%	-17.21%
CNTA Centessa Pharmaceuticals	0.00%	-9.70%	+6.22%	-30.92%	+37.01%
INDV Indivior	0.00%	-7.43%	+21.73%	+16.25%	-37.45%
KIN Kindred Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3904 of 5 stars	3.3	2.0	0.0	4.2	4.1	0.8	1.9
CNTA Centessa Pharmaceuticals	3.3353 of 5 stars	4.5	1.0	0.0	0.0	2.9	3.3	0.6
INDV Indivior	3.3254 of 5 stars	3.6	3.0	0.0	0.0	2.6	1.7	1.9
KIN Kindred Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.56	Moderate Buy	$56.00	92.18% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.00	105.32% Upside
INDV Indivior	3.25	Buy	$15.00	32.28% Upside
KIN Kindred Biosciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest KIN, AGIO, INDV, and CNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	CNTA Centessa Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$6.00
5/8/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
5/2/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$74.00 ➝ $71.00
3/31/2025	CNTA Centessa Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$38.00
3/26/2025	CNTA Centessa Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/7/2025	CNTA Centessa Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$27.00 ➝ $27.00
3/6/2025	INDV Indivior	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $13.00
2/24/2025	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$58.00 ➝ $58.00

(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$37.04M	45.57	N/A	N/A	$27.02 per share	1.08
CNTA Centessa Pharmaceuticals	$6.85M	255.56	N/A	N/A	$2.42 per share	5.43
INDV Indivior	$1.17B	1.34	$2.30 per share	4.94	N/A	∞
KIN Kindred Biosciences	$42.16M	9.97	N/A	N/A	$1.75 per share	5.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.24	2.57	N/A	N/A	1,845.92%	-2.51%	-2.26%	N/A
CNTA Centessa Pharmaceuticals	-$151.09M	-$1.99	N/A	N/A	N/A	N/A	-52.13%	-38.01%	5/12/2025 (Estimated)
INDV Indivior	$2M	-$0.31	N/A	6.63	N/A	-3.96%	-241.73%	15.09%	7/24/2025 (Estimated)
KIN Kindred Biosciences	-$21.80M	-$0.55	N/A	N/A	N/A	-529.26%	-54.19%	-39.76%	N/A

Latest KIN, AGIO, INDV, and CNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	AGIO Agios Pharmaceuticals	-$1.80	-$1.55	+$0.25	-$1.55	$9.86 million	$8.73 million
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million
3/24/2025	Q4 2024	CNTA Centessa Pharmaceuticals	-$0.38	-$0.34	+$0.04	-$0.84	N/A	N/A
2/20/2025	Q4 2024	AGIO Agios Pharmaceuticals	-$1.69	-$1.74	-$0.05	-$1.74	$9.35 million	N/A
2/20/2025	Q4 2024	INDV Indivior	$0.32	$0.32	N/A	$0.07	$262.35 million	$298.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
KIN Kindred Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	11.90	11.56
CNTA Centessa Pharmaceuticals	0.15	21.52	21.52
INDV Indivior	N/A	0.83	0.65
KIN Kindred Biosciences	0.19	7.02	7.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
CNTA Centessa Pharmaceuticals	82.01%
INDV Indivior	60.33%
KIN Kindred Biosciences	66.89%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
CNTA Centessa Pharmaceuticals	11.59%
INDV Indivior	N/A
KIN Kindred Biosciences	13.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	57.92 million	54.47 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.18 million	116.56 million	Optionable
INDV Indivior	1,164	137.88 million	N/A	Not Optionable
KIN Kindred Biosciences	63	45.46 million	N/A	Optionable

KIN, AGIO, INDV, and CNTA Headlines

Recent News About These Companies

Ernest Mario

October 24, 2024 | centraljersey.com

Duke Flags Lowered: Ernest Mario, Founding Chair of DUHS Board of Directors, Dies

October 23, 2024 | today.duke.edu

Why Silicon Valley falls prey to ‘charisma distortion,’ according to investor and Google X founding member Tom Chi

August 19, 2024 | msn.com

Willow Smith announces the new release date of her first book “Black Shields Maiden”

April 23, 2024 | msn.com

Explosive Growth Projected in US Pet Medication Market, the Industry to Reach $17.90 Billion by 2029 - Exclusive Focus Insight Report by Arizton

April 2, 2024 | prnewswire.co.uk

Tory party donor Frank Hester to be investigated for 'racist comments' by West Yorkshire Police

March 22, 2024 | mirror.co.uk

Nagaland Assembly passes resolution against Centre’s move to fence India-Myanmar border

March 2, 2024 | scroll.in

Kindred Hospital East Greensboro

February 23, 2024 | health.usnews.com

Japan's Sony terminates $10 bln Zee India merger

January 22, 2024 | reuters.com

European Shares Edge Higher With ECB Meeting In The Spotlight

January 22, 2024 | markets.businessinsider.com

Earnings Optimism May Contribute To Continued Strength On Wall Street

January 22, 2024 | markets.businessinsider.com

Authorities investigating garage fire in Kindred

December 28, 2023 | valleynewslive.com

Honoree: Nanxi Liu

December 17, 2023 | latimes.com

Start-up Cradle tucks in $24m for protein engineering AI

November 29, 2023 | pharmaphorum.com

Startup Cradle tucks in $24m for protein engineering AI

November 29, 2023 | pharmaphorum.com

Global Companion Animal Pharmaceuticals Market Size To Worth USD 27.16 Billion by 2032 | CAGR of 5.7%

November 8, 2023 | finance.yahoo.com

Mizoram Assembly elections: Incumbent MNF faces tough challenge; a look at key candidates and constituencies

November 6, 2023 | devdiscourse.com

Mat-Su Assembly member agrees to pay $77,500 for extending property into lake and wetlands

October 8, 2023 | adn.com

Kindred Hospital-Dayton

October 7, 2023 | health.usnews.com

Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development

September 21, 2023 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Is Energy Transfer Undervalued or a Value Trap?
By Chris Markoch | May 8, 2025
View Is Energy Transfer Undervalued or a Value Trap?
Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost
By Leo Miller | May 7, 2025
View Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost
Viking Therapeutics Stock Pops But Struggles to Hold Gains
By Chris Markoch | April 16, 2025
View Viking Therapeutics Stock Pops But Struggles to Hold Gains
3 Dividend Kings Outshining the Market in 2025
By Ryan Hasson | April 30, 2025
View 3 Dividend Kings Outshining the Market in 2025
Gold Is Making All-Time Highs, But So Is This Quiet Metal
By Gabriel Osorio-Mazilli | April 21, 2025
View Gold Is Making All-Time Highs, But So Is This Quiet Metal

KIN, AGIO, INDV, and CNTA Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$29.14 +1.82 (+6.66%)

Closing price 04:00 PM Eastern

Extended Trading

$29.14 0.00 (0.00%)

As of 04:38 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Centessa Pharmaceuticals NASDAQ:CNTA

$13.15 +0.85 (+6.91%)

Closing price 04:00 PM Eastern

Extended Trading

$13.16 +0.00 (+0.04%)

As of 04:01 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Indivior NASDAQ:INDV

$11.34 +0.26 (+2.35%)

Closing price 04:00 PM Eastern

Extended Trading

$11.36 +0.02 (+0.13%)

As of 07:58 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Kindred Biosciences NASDAQ:KIN

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time